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Accepted 10 December 2015Multiple sclerosis associated retrovirus envelope protein (MSRV-Env) was repeatedly detected in brain lesions
and blood of multiple sclerosis (MS) patients. We performed the ﬁrst pharmacological characterisation of
MSRV-Env on recombinant and native human TLR4. MSRV-Env is a full and highly potent TLR4 agonist of endog-
enous origin. MSRV-Env induces TLR4-dependent pro-inﬂammatory stimulation of immune cells in vitro and
in vivo, and impairs oligodendrocytes precursor cells differentiation to myelinating oligodendrocytes. MSRV-
Envmay play a role in chronic inﬂammation and impaired remyelination inMS. GNbAC1, a selective monoclonal
antibody, antagonizes MSRV-Env pathogenic effects and represents an innovative therapeutic approach of MS.
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Multiple sclerosis1. Introduction
Human endogenous retroviruses (HERV) represent approximately
8% of the human genome and result from integration of exogenous
retroviruses that infected the germline of their hosts during primate
evolution (Belshaw et al., 2004). HERV belong to the superfamily of
repeated and transposable elements and retain properties of mobile
genetic elements although most contemporary HERV copies are
inactivated by mutations, deletions, or silenced by epigenetic modiﬁca-
tions (Belshaw et al., 2005; Romanish et al., 2010). The ﬁrst description
of retrovirus-like particles with reverse transcriptase activity in
leptomeningeal and macrophage cell cultures from multiple sclerosis
(MS) patients suggested a viral origin of the disease (Perron et al.,
1991). However, further molecular characterisation of this Multiplebrospinal ﬂuid; DAMP, danger-
gic encephalomyelitis; ELISA,
endogenous retrovirus; hOPC,
peripheral blood mononuclear
lin; IL-6, interleukine 6; LPS, li-
sclerosis associated retrovirus;
combinant surface domain of
surface domain of MSRV-Env;
tical density; orf, open reading
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. This is an open access article underSclerosis-associated RetroVirus (MSRV) revealed that it was not a
classical infectious exogenous retrovirus but the forming member of
the W family of HERV (HERV-W) (Blond et al., 1999; Komurian-Pradel
et al., 1999; Perron et al., 1997). Though HERV-W elements are usually
truncated or lack open reading frames (orf), several chromosomal
copies retain potential orf for viral proteins (Voisset et al., 2000).
Interestingly, certain exogenous viral agents can trigger the reactivation
of MSRV copies, particularly Herpesviridae which have been often
associated with MS epidemiology without demonstrating a causative
role in the disease. Thus, reactivation of silent MSRV, which exhibits
pathogenic properties, by such environmental infectious agents may
be the missing link between environment and MS onset (Perron and
Lang, 2010). Following the initial isolation of MSRV particles from
cerebral tissues of MS patients, numerous independent studies in
humans performed by two research groups have associated MS with
an elevated MSRV expression, in particular its MSRV envelope protein
(MSRV-Env) in serum or its corresponding RNA in human peripheral
blood mononuclear cells (hPBMC) (Arru et al., 2007; Mameli et al.,
2007; Perron et al., 2012). Furthermore, MSRV-Env protein was detect-
ed on the cell surface of inﬁltratedmacrophages and activatedmicroglia
inMS brain lesions, but not in normal appearingwhitematter or control
brains (Kremer et al., 2013; Perron et al., 2012).
MS is a devastating chronic inﬂammatory demyelinating disease of
the central nervous system (CNS). Although its aetiology is not elucidat-
ed yet, MS probably has an autoimmune component. The presence of
inﬁltrating T-cells, monocytes and macrophages in the brain lesions ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the mediation of cerebral damages (Weiner, 2009). Several studies
show that MSRV virions or its envelope protein elicit immuno-
pathogenic and pro-inﬂammatory responses on human T lymphocytes
and hPBMC (Perron et al., 2001; Rolland et al., 2006). More recently,
Kremer et al. (2013, 2014) showed that MSRV-Env induces the expres-
sion of pro-inﬂammatory cytokines and inducible NO synthase by
oligodendrocyte precursors cells (OPC) in culture. Furthermore, the
authors report that MSRV-Env decreases the differentiation capacity of
rat OPC to mature myelinating cells. Some of these MSRV-Env effects
were attributed to toll-like receptor 4 (TLR4) activation though not
characterised (Kremer et al., 2013; Rolland et al., 2006). TLR signalling
plays a crucial role in innate immunity through initiation of host defence
responses to microbial infection (Hanke and Kielian, 2011) and these
observations suggest that MSRV-Env pathogenic properties may be
involved in MS.
As the aetiology of MS is unknown, there are no causal treatments of
the disease. Thoughmajor progresses have been recently achievedwith
new oral treatments, existing therapies only alter the course of MS and
once the disease develops it is lifelong. Furthermore available treat-
ments, which are approved for the relapse-remitting form of MS, are
in general strong immunomodulators associatedwith substantial safety
risks, but they have shown only marginal or no effect in the progressive
forms of the disease. There is a critical medical need for innovative and
safer MS treatments, in particular dedicated to the progressive forms of
the disease where remyelination impairments prevail (Curtin and
Hartung, 2014). Thus, as MSRV-Env expression is associated with MS,
exhibits pro-inﬂammatory properties and potentially impairs brain
remyelination, a humanised monoclonal antibody targeting MSRV-
Env, named GNbAC1, has been developed as an innovative therapeutic
approach for MS (Curtin et al., 2015).
We performed the ﬁrst pharmacological characterisation of MSRV-
Env interaction with recombinant human TLR4 (hTLR4) and demon-
strated that MSRV-Env is an endogenous and highly potent full agonist
of hTLR4. Then, we performed the characterisation of MSRV-Env
interaction with native hTLR4 expressed by hPBMC and human OPC
(hOPC). This study conﬁrms previous reports suggesting MSRV-Env
pro-inﬂammatory properties in vitro and we show that this MSRV-
Env feature is mirrored in vivo. Furthermore, we show that MSRV-Env
impairs hOPC differentiation to mature myelinating oligodendrocytes
through hTLR4 activation. GNbAC1 antagonizes all the pathogenic
effects of MSRV-Env investigated, supporting the fact that GNbAC1
may provide a new and targeted therapeutic approach to the treatment
of MS.
2. Materials and methods
2.1. Recombinant proteins and chemicals
Three different recombinant MSRV-Env proteins were used in this
study. The full length MSRV-Env-T protein was produced from plasmid
pV14 encompassing the complete orf of MSRV-Env cloned from MSRV
virion RNA (58 kDa, 542 aminoacids, GenBank no. AF331500.1).
MSRV-Env-SU is a 33 kDa and 293 aminoacids fraction of the
extracellular domain of MSRV-Env-T. Both proteins were produced in
Escherichia coli. MSRV-Env-SUG is the glycosylated form of MSRV-Env-
SU and was produced in HEK 293 human cell line. Recombinant
MSRV-Env proteins were produced by Protein'Expert (Grenoble,
France) as previously described (Perron et al., 2013; Rolland et al.,
2005, 2006).
GNbAC1 is a humanized monoclonal antibody of the IgG4/kappa
class that selectively bindswith high afﬁnity to the extracellular domain
of MSRV-Env protein (Curtin et al., 2012, 2015). GNbAC1 vehicle
(20 mM histidine, 5% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH
6.0) was systematically used as a negative control in all experiments.
Natalizumab (Biogen-Dompé, Zug, Switzerland), another humanizedIgG4 antibody speciﬁc for the cell adhesion molecule α4-integrin, was
systematically used as a GNbAC1 isotype control in this study but not
in hPBMC experiments since it exerts a direct effect in this model.
LPS is the prototypical TLR4 agonist and was used as a positive
control in experiments performed with recombinant hTLR4. CD14 acts
as a co-receptor of TLR4 and anti-human CD14 or TLR4 antibodies
were used as selective blockers of the hTLR4/CD14 receptor complex.
LPS-RS is a characterized competitive LPS antagonist extracted from
Rhodobacter sphaeroides (Stevens et al., 2013), and Cli-095 is a selective
intracellular suppressor of TLR4 signalling (Kawamoto et al., 2008;
Matsunaga et al., 2011). LPS-EK Ultrapure, anti-human CD14 IgA, anti-
human TLR4 IgG and corresponding isotype controls antibodies, LPS-
RS, and Cli-095 were purchased from Invivogen (Toulouse, France).
Polymyxin B (PMB) inhibits LPS liaison to LPS binding protein (LBP),
was used as a selective LPS inhibitor and was purchased from Sigma
(Buch, Switzerland). Mouse anti-CNPase (2′,3′-Cyclic nucleotide-3′-
phosphohydrolase) and anti-MBP (Myelin Basic Protein) antibodies
were purchased from Covance (Paris, France).
2.2. HEK-blue™-TLR4 cells culture and TLR4 signalling assays
HEK-Blue™-hTLR4 and HEK-Blue™-mTLR4 cells were obtained by
co-transfection of the human or murine TLR4, MD-2 and CD14 co-
receptor genes, and an inducible SEAP (secreted embryonic alkaline
phosphatase) reporter gene into HEK293 cells. The SEAP reporter gene
is placed under the control of an Il-12 p40 minimal promoter fused to
ﬁve NF-κB and AP-1 binding sites. Stimulation with a TLR4 agonist
activates NF-κB and AP-1which induce the production of SEAP assessed
by a colorimetric assay. HEK-Blue™ Null2 is the parental negative
control cell line of HEK-Blue™-hTLR4 and HEK-Blue™-mTLR4 cells.
HEK-Blue™-hTLR4, HEK-Blue™ Null2 and HEK-Blue™-mTLR4
(Invivogen, Toulouse, France) culture was performed according to
supplier's recommendations. In ﬁrst experiments, HEK-Blue™-hTLR4
cells were classically stimulated by agonists and/or antagonists for
24 h in the recommended culturemedium. In subsequent pharmacolog-
ical investigations, themanufacturer's protocol was adapted to a 30min
stimulation with agonists and/or antagonists followed by a 15.5 h incu-
bation before revelation, in Pro293A-CDM (Lonza, Basel, Switzerland), a
serum-free culture medium supplemented with 50 U mL−1 penicillin
(Life Technologies, Basel, Switzerland), 50 μg mL−1 streptomycin (Life
Technologies, Basel, Switzerland) and 100 μg mL−1 Normocin
(Invivogen, Toulouse, France). TLR4 activation was revealed colorimet-
rically with QUANTI-Blue™ detection assay (Invivogen, Toulouse,
France). Optical densities were measured with a Biotek EL800
microplate reader at 650 nm with the KC Junior software (Biotek,
Luzern, Switzerland).
2.3. Human PBMC cultures and cytokines ELISA
Buffy coats from healthy donors were purchased from the Centre
for Blood Transfusion of Geneva (Switzerland). Accordingly, this
study was not reviewed by an Institutional Review Board or Ethics
Committee as all healthy donors signed a written Informed Consent
Form, documented at the Centre for Blood Transfusion of Geneva,
allowing the commercial use of their blood and blood components
for medical research after deﬁnitive anonymization. All individual
set of experiments presented here were performed with hPBMC
from the same blood donor. hPBMC were isolated by Ficoll separa-
tion from buffy coats, aliquoted and frozen at −80 °C. For MSRV-
Env-T concentration-response experiments, hPBMC frozen in
DMSO 10% in foetal bovine serum (FBS, Biowest, Nuaillé, France)
were thawed and directly stimulated for 24 h with MSRV-Env-T in
96-well plates in FBS 10%, penicillin/streptomycin 1%, MEM non-
essential amino acids solution 1%, and sodium pyruvate 1 mM in
RPMI culture media (Gibco, Life Technologies, Basel, Switzerland).
For MSRV-Env-T inhibition experiments, hPBMC frozen in CTL-
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thawed and directly stimulated for 24 hwithMSRV-Env-T in 96-well
plates in serum-free medium (CTL-Test Medium, Cellular Technolo-
gy Ltd., Bonn, Germany). Then, culture supernatants were collected
and frozen at−20 °C before quantiﬁcation of IL-6 and TNF-α by ded-
icated Ready-SET-Go ELISA according to manufacturer's instructions
(eBioscience, Vienna, Austria).
2.4. Cytokines induction in mice
Thirty adult C57BL/6 female mice (9–12 weeks old, Taconic Farms,
Germantown, NY)were used in this study, performed by Hooke Labora-
tories (Lawrence, MA). All procedureswere conducted in accordance to,
and speciﬁcally approved by, the Hooke's Institutional Animal Care and
Use Committees (Hooke's IACUC, permit number IC-CytokineProd-
1312KO2_Amd1), which relies on NIH guidelines, and reported in
accordance to the ARRIVE guidelines for reporting animal experiments
(Kilkenny et al., 2010). Blood collection was performed under CO2
anaesthesia, and all efforts were made to minimize suffering. Mice
were housed 5 per cage, in a temperature and humidity-controlled
room with a 12 h light/dark cycle and free access to food and water
(milliQ puriﬁed and UV sterilized). All mice were acclimated for at
least 7 days before being assigned to 3 groups in a balanced manner to
achieve similar weight at the beginning of the study. MSRV-Env-T
(3.3 mg kg−1) was administered intravenously along with correspond-
ing GNbAC1 vehicle or together with GNbAC1 (1.6 mg kg−1), at a
constant volume of 140 μL per mice (mean weight of 18.3 g per mice
in both groups). Onemouse per groupwas rejected because administra-
tion failed. The control group (n = 10) was administered by
corresponding MSRV-Env-T and GNbAC1 vehicles. Two hours after
compounds administration, mice were deeply anesthetised with CO2
and 0.2 to 0.4 mL of blood per mouse was collected by cardiac puncture
before CO2 euthanasia. Serum was isolated and frozen before
subsequent determination of IL-6 and TNF-α concentrations by Cyto-
metric Bead Array analyses according to manufacturer's instructions
(Becton-Dickinson, San Jose, CA, USA).
2.5. Human OPC culture and immunocytochemistry
Oligodendrocytes precursor cells isolated from human brain tissue
and corresponding culture reagents were purchased from ScienCell
Research Laboratories (Carlsbad, CA). The complete hOPC culture
medium (OPCM) was reconstituted by addition of OPC growth solution
and penicillin/streptomycin to the OPCM according to manufacturer's
recommendations. After thawing, hOPC were diluted in OPCM and
seeded (7000 cells/cm2 = 10,000 cells per well) into 8-wells labtek
culture vessels (Nunc, Roskilde, Denmark) previously coated with
poly-L-lysine (0.01%, Sigma, Saint Quentin Fallavier, France). Pharmaco-
logical treatmentswere applied to hOPC directly after cellswere seeded.
Then, hOPCwere incubated at 37 °C, 5% CO2 for 24 h or 72h before being
ﬁxed in a 4% paraformaldehyde in Phosphate Buffer Saline (PBS, Life
Technologies, Saint Aubin, France) solution at room temperature for
1 h. OPCM was changed the next day to remove unattached or dead
cells in the cultures treated for 72 h. After ﬁxation, hOPC were washed
3 times with PBS and non-speciﬁc binding sites were saturated with a
10% foetal bovine serum (FBS), 0.01% Triton X100 in PBS saturation so-
lution, incubated for 1 h at 37 °C. Then, hOPCwere incubated for 12 h at
4 °C with mouse anti-CNPase (24 h treatments) or mouse anti-MBP
(72 h treatments) primary antibodies diluted 1/250 and 1/150 respec-
tively in the saturation solution. Then, cells were washed 3 times with
PBS, and incubated with a FITC-conjugated goat anti-mouse secondary
antibody (Millipore, Molsheim, France; 1/200 in saturation solution)
for 1 h at 37 °C. After 3 washes with PBS, the slides were mounted
with Vectastain®mountingmedium containing DAPI (Vector Laborato-
ries, Burlingame, CA). Staining was visualized by ﬂuorescent microsco-
py using an Axioscope microscope (Zeiss, Feldbach, Switzerland).Myelin markers immunoreactive cells and total number of cells were
counted in 10 different randomized ﬁelds per culture chamber.
2.6. Statistical analysis
Data were modelled by non-linear regression to analyse
concentration-response curves and to generate Schild-plot and EC50 or
IC50 values. Kolmogorov-Smirnov normality test was applied to all
data sets. Student's t-testwas used to compare each group to the control
group when data passed the normality test, otherwise Mann–Whitney
rank sum test was used to compare non-normal data. p values b 0.05
were considered signiﬁcant. Statistical analyses were performed with
SigmaStat 3.5 (Systat inc., San Jose, CA, USA), Prism 5.04 (GraphPad
Software, La Jolla, CA) was used to plot the data and for calculations.
3. Results
3.1. Pharmacological characterisation of MSRV-Env, an agonist of
recombinant human TLR4
HEK-Blue™ hTLR4 cells were designed for themonitoring of recom-
binant hTLR4 activation through a SEAP reporter gene. In this model
LPS, the full length MSRV-Env (MSRV-Env-T), the surface domain of
MSRV-Env (MSRV-Env-SU) and the glycosylated MSRV-Env-SU
(MSRV-Env-SUG) induce a concentration-dependent activation of re-
combinant hTLR4 (Fig. 1a). The maximal effects of LPS, MSRV-Env-T
and MSRV-Env-SU (absorbance at 650 nm of 1.08 ± 0.01, 0.89 ± 0.01
and 1.07 ± 0.01 respectively) are not signiﬁcantly different and
maximal MSRV-Env-SUG effect was not achieved in these conditions.
Submaximal concentrations of LPS and MSRV-Env-T do not stimulate
the parental negative control HEK-Blue™ Null2 cells, which suggests
that MSRV-Env behaves as a full agonist of recombinant hTLR4 in this
model (Fig. 1a).
LPS-induced recombinant hTLR4 activation is inhibited by anti-CD14
or anti-TLR4 antibodies and by PMB (−95%,−82% and−97% respec-
tively) but not by corresponding isotype control antibodies (Fig. 1b).
In contrast, the recombinant hTLR4 activation by MSRV-Env-T is
inhibited by an anti-CD14 antibody (−68%) but not by its isotype
control or PMB. MSRV-Env-T effect is strongly antagonized by an anti-
TLR4 antibody (−96%) and slightly but signiﬁcantly by the anti-TLR4
isotype control (−13%). However, the inhibitions induced by the anti-
TLR4 antibody and its isotype control are signiﬁcantly different (Fig.
1c). MSRV-Env-SU effect on the recombinant hTLR4 is inhibited by
anti-CD14 or anti-TLR4 antibodies and by PMB (−83%, −72% and
−9% respectively) but not by corresponding isotype control antibodies
(Fig. 1d). The recombinant hTLR4 activation induced byMSRV-Env-SUG
is antagonized by anti-CD14 or anti-TLR4 antibodies (−81% and−66%
respectively) and by PMB, though not signiﬁcantly (−21%). MSRV-Env-
SUG effect is not affected by corresponding isotype control antibodies
(Fig. 1e). The speciﬁc inhibition of all forms of MSRV-Env by anti-
CD14 and anti-TLR4 antibodies suggests further thatMSRV-Envbehaves
as an agonist of recombinant hTLR4 in this model.
Next, we performed a complete pharmacological proﬁling of MSRV-
Env effects on recombinant hTLR4. LPS effect is suppressed by LPS-RS, a
competitive LPS antagonist, and by Cli-095, a speciﬁc TLR4 signalling in-
hibitor (−100%). LPS effect is slightly though signiﬁcantly inhibited by
GNbAC1, a humanized monoclonal IgG4 antibody targeting MSRV-Env
(−16%). However, this small GNbAC1 effect is not speciﬁc as it is
mimicked by corresponding GNbAC1 vehicle or by its isotype control
(−18% and −33% respectively) (Fig. 2a). In contrast to LPS, MSRV-
Env-T effect is inhibited by GNbAC1 (−53%) but not by corresponding
GNbAC1 vehicle or isotype control (Fig. 2b). Similarly, MSRV-Env-SU
and MSRV-Env-SUG effects are antagonized by GNbAC1 (−33% and
−46% respectively) without being affected by GNbAC1 vehicle and
isotype control (Fig. 2c and d). The effects of all MSRV-Env preparations
are suppressed by LPS-RS and Cli-095, suggesting further that MSRV-
Fig. 1. Effects of polymyxin B, anti-CD14 and anti-TLR4 antibodies on hTLR4 concentration –dependent activation induced by LPS, MSRV-Env-T, MSRV-Env-SU, and MSRV-Env-SUG. a:
HEK-blue™ hTLR4 cells were stimulated 24 h with increasing concentrations of LPS (red dots), MSRV-Env-T (black dots), MSRV-Env-SU (open squares), and MSRV-Env-SUG (black
squares). hTLR4 speciﬁcity was veriﬁedwith parental HEK-blue™ Null2 negative control cells which were not activated by highest LPS (red asterisk) or MSRV-Env-T (open dots) concen-
trations. b-e: HEK-blue™ hTLR4 cells were stimulated 24 hwith LPS (b; 1 or 3 EUmL−1),MSRV-Env-T (c; 1 or 3 nM),MSRV-Env-SU (d; 30 or 100 nM), andMSRV-Env-SUG (e; 3 μgmL−1)
alone or together with PMB (80 U mL−1), anti-CD14, anti-TLR4, and corresponding isotype controls (IC-CD14, IC-TLR4) antibodies (10 μg mL−1). hTLR4 activation was monitored color-
imetrically using a SEAP reporter gene placed under the control of an NF-κB inducible promoter. Data are expressed as absorbance at 650 nm (a) or as % of control response to LPS, MSRV-
Env-T, MSRV-Env-SU, and MSRV-Env-SUG alone (b–e; in the absence of antagonist; OD 650 nm of 0.40 ± 0.03, 0.49 ± 0.06, 0.56± 0.03, and 0.52± 0.04 respectively) and are Means ±
SEM from 6 to 12 experiments. **P b 0.01, ***P b 0.001 versus agonist alone.
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RS and an anti-TLR4 antibody (Fig. 3b) inhibit MSRV-Env-T in a
concentration-dependent manner, with IC50 of 5.8 ± 0.2 nM, 274 ±1 nM, 161 ± 7 g mL−1 and 218 ± 29 g mL−1 respectively. A complete
antagonism of MSRV-Env-T by GNbAC1 was not achieved in this
model. The concentration-dependent activation of recombinant hTLR4
Fig. 2. Effects of GNbAC1, LPS-RS and Cli-095 on hTLR4 activation induced by LPS, MSRV-Env-T, MSRV-Env-SU, and MSRV-Env-SUG. HEK-blue™ hTLR4 cells were stimulated 30minwith
LPS (a; 3 EU mL−1), MSRV-Env-T (b; 3 nM), MSRV-Env-SU (c; 30 nM), and MSRV-Env-SUG (d; 3 μg mL−1) alone or together with GNbAC1 (50 nM), corresponding GNbAC1 vehicle or
isotype (IC-GNbAC1, 50 nM) controls, LPS-RS (300 ngmL−1), or Cli-095 (1 μM). Then, cells were subsequently incubated during 15.5 h with antagonists only. hTLR4 activation was mon-
itored colorimetrically using a SEAP reporter geneplaced under the control of anNF-κB inducible promoter. Data are expressed as % of control response to LPS,MSRV-Env-T,MSRV-Env-SU,
andMSRV-Env-SUG alone (in the absenceof antagonist; OD650nmof 0.24±0.02, 0.17±0.01, 0.34±0.01, and0.09±0.01 respectively) and areMeans±SEM from6 to 12 experiments.
***P b 0.001 versus agonist alone.
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3c). MSRV-Env-T concentration-response curve is shifted rightward by
increasing concentrations of LPS-RSwith no decrease in themaximal ef-
fect. The slope of the corresponding Schild analysis is 0.94±0.03,with a
95% conﬁdence interval that includes 1.00 (0.79 to 1.10), demonstrating
that LPS-RS is a competitive antagonist of MSRV-Env-T (Fig. 3d).3.2. TLR4-dependent pro-inﬂammatory properties of MSRV-Env are
inhibited by GNbAC1 in vitro and in vivo
We then sought to investigate MSRV-Env interactions with native
hTLR4 in cultured hPBMC. A 24 h stimulationwithMSRV-Env-T induces
a potent and concentration-dependent release of the pro-inﬂammatory
cytokines IL-6 (EC50 of 0.20 ± 0.11 nM, maximal release of 9866 ±
923 pg mL−1 at 3 nM; Fig. 4a) and TNF-α (EC50 of 1.08 ± 0.09 nM,
maximal release of 409 ± 37 pg mL−1 at 3 nM; Fig. 4b) in cultured
hPBMC. The MSRV-Env-T induced release of IL-6 (Fig. 4c) and TNF-α
(Fig. 4d) is antagonized by GNbAC1 (−69% and −64% respectively)
but not by corresponding GNbAC1 vehicle, by an anti-TLR4 (−88%
and−68% respectively) antibody but not by its corresponding isotype
control, by LPS-RS (−93% and −95% respectively) and by Cli-095
(−72% and−80% respectively). Similarly to observations made with
recombinant hTLR4, MSRV-Env is a highly potent agonist of native
hTLR4 expressed by hPBMC, is speciﬁcally inhibited by GNbAC1 in thismodel, which therefore conﬁrms MSRV-Env strong pro-inﬂammatory
properties.
Studies performed with murine TLR4 (mTLR4) expressed in HEK-
Blue™ mTLR4 cells demonstrated that MSRV-Env-T is also a highly
potent mTLR4 agonist, with an EC50 of 0.085 ± 0.001 nM in this
model (Fig. 4e). Thus, we have investigated if MSRV-Env presents pro-
inﬂammatory properties and assessed GNbAC1 putative beneﬁcial
effect in mice. MSRV-Env-T injected intravenously at 3.3 mg kg−1
induces a strong release of IL-6 (+10,919 ± 1738 pg mL−1 above the
basal level of 3022 ± 590 pg mL−1 determined in control mice) and
TNF-α (+344 ± 49 pg mL−1 above the basal level of 185 ±
23 pg mL−1) in mice blood 2 h after its administration. Concomitant
GNbAC1 administration (1.6 mg kg−1) antagonized the release of IL-6
(+3365 ± 978 pg mL−1; −69%) and TNF-α (+176 ± 50 pg mL−1;
−49%) induced by MSRV-Env-T in mice (Fig. 4f).
3.3. MSRV-Env-T induced impairment of hOPC differentiation to
myelinating cells is TLR4-dependent and suppressed by GNbAC1
Then, we have investigated MSRV-Env interactions with native
hTLR4 and assessed GNbAC1 potential beneﬁt in primary cultured
hOPC. We detect the expression of hTLR4 on the surface of hOPC
cultured for 72 h by immunocytochemistry performed with a selective
anti-TLR4 antibody (Fig. 5a). A 24 h incubation with MSRV-Env-T in-
duces a decrease of the proportion of hOPC expressing CNPase, the
Fig. 3. Concentration-dependent inhibition of MSRV-Env-T induced recombinant hTLR4 activation by GNbAC1 and selective TLR4 antagonists. HEK-blue™ hTLR4 cells were stimulated
24 h with MSRV-Env-T (3 nM) alone or together with increasing concentrations of Cli-095 (a), LPS-RS, an anti-TLR4 antibody or its isotype control (IC-TLR4; b). For GNbAC1, HEK-
blue™ hTLR4 cells were stimulated 30 min with MSRV-Env-T (3 nM) alone or together with increasing concentrations of GNbAC1 or its isotype control (IC-GNbAC1; a), then cells
were subsequently incubated during 15.5 hwith GNbAC1 only. hTLR4 activationwasmonitored colorimetrically using a SEAP reporter gene placed under the control of anNF-κB inducible
promoter. Data are expressed as % of control response to MSRV-Env-T alone (in the absence of antagonist; OD 650 nm of 0.40± 0.03) and areMeans± SEM from 6 to 12 experiments. c:
Increasing concentrations of LPS-RS produce increasing rightward shifts in the concentration-response curve toMSRV-Env-T. d: The Schild-plot of these responses constructed by plotting
log(concentration ratio – 1) by concentrations of LPS-RS. The Schild-plot slope is 0.94 ± 0.03 and is not different than 1.00, suggesting a single site competitive antagonism. Data are
expressed as % of control maximal response to MSRV-Env-T (10 nM, in the absence of antagonist) and are Means ± SEM from 6 to 9 experiments.
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drocytes (−24%). Similarly, a 72 h stimulation with MSRV-Env-T
induces a decrease of the proportion of hOPC expressing MBP, a late
marker of hOPC differentiation to myelinating cells (−35%) (Fig. 5b).
The decrease of CNPase and MBP expressions induced by MSRV-
Env-T in hOPC is antagonized by GNbAC1 (−94% and −100%
respectively), by LPS-RS (−100% for both myelination markers) and
by Cli-095 (−100% and −88% respectively) (Fig. 5c). GNbAC1
concentration-dependently, potently and fully antagonizes these
hTLR4-mediated MSRV-Env-T effects on CNPase (IC50 = 7.79 ±
0.24 nM) and MBP (IC50 = 5.12 ± 0.14 nM) expressions (Fig. 5d), and
GNbAC1 effect is speciﬁc since it was not reproduced by
corresponding GNbAC1 vehicle or by its isotype control (Fig. 5c).
4. Discussion and conclusions
Pro-inﬂammatory properties of MSRV Envelope protein were previ-
ously reported and attributed to a TLR4 stimulation (Perron et al., 2001;
Rolland et al., 2006; Saresella et al., 2009). Based on a functional assay of
recombinant hTLR4 stimulation, the data presented here demonstrates
that all available forms of recombinant MSRV-Env present an identical
pharmacological proﬁle and behave as full agonists of recombinant
hTLR4. Similarly to LPS, MSRV-Env effects are antagonized by LPS-RS,
a competitive LPS antagonist extracted from R. sphaeroides (Stevens
et al., 2013), by Cli-095, a selective inhibitor of TLR4 signalling
(Kawamoto et al., 2008; Matsunaga et al., 2011), and by anti-CD14 or
anti-TLR4 antibodies. LPS-RS also behaves as a competitive MSRV-Env-T antagonist, showing that MSRV-Env binds TLR4 close to or in the
same binding pocket as LPS. Stimulation of recombinant hTLR4 by
MSRV-Env-T is concentration-dependent and highly potent, with an
EC50 in the picomolar range, which demonstrates that hTLR4 is a
major MSRV-Env receptor. Syncytin-1 is a domesticated envelope pro-
tein from the HERV-W family. It is mainly expressed in human placenta
during pregnancy, where it mediates syncytium formation through an
interaction with the sodium-dependent neutral amino-acid trans-
porters ASCT-1 and ASCT-2 (Cheynet et al., 2006; Lavillette et al.,
2002). MSRV-Env and Syncytin-1 transcripts only differ by an insertion
of 12 nucleotides in the corresponding trans-membrane domain of the
proteins, and the lack of discriminating tools has generated confusing
reports in the literature (Dolei et al., 2015; Laufer et al., 2009). Thus,
ASCT-1 and ASCT-2 transporters may also function as additional
MSRV-Env receptors, apart from its potent binding to hTLR4.
Polymyxin B is a selective LPS inhibitor (Scott et al., 2000). It does
not modulate MSRV-Env-T but it inhibits approximately 20% of MSRV-
Env-SU and MSRV-Env-SUG effects, which reveals trace amounts of
LPS remains in these preparations. For this reason, all further studies
presented here were performed with MSRV-Env-T, which is a well
characterised preparation. Traces of MSRV-Env and LPS rapidly elicit a
strong and irreversible stimulation of HEK-Blue ™ hTLR4 cells. We
have progressively adapted themanufacturer's protocol (24 h of stimu-
lation by agonists) to a new one suitable for antagonists' pharmacology
by reducing the stimulation to 30min followed by 15.5 h of incubation.
Furthermore, we observed that trace amounts of LPS contaminants in
several foetal bovine serum lots (Kirikae et al., 1997) affect this model,
Fig. 4.MSRV-Env, a potent pro-inﬂammatory agonist of native human andmurine TLR4, is inhibited byGNbAC1. Twenty four hours incubationwithMSRV-Env-T induces a concentration-
dependent release of IL-6 (a) and TNF-α (b) in human PBMC in culture. MSRV-Env-T induced release of IL-6 (c) and TNF-α (d) is inhibited by selective TLR4 antagonist: hPBMC were
stimulated 24 h with MSRV-Env-T (1–3 nM) alone or together with GNbAC1 (200 nM), corresponding GNbAC1 vehicle, anti-TLR4 or corresponding isotype control (IC-TLR4;
2.5 μg mL−1) antibodies, LPS-RS (10 ng mL−1), or Cli-095 (0.3 μM). Data are expressed as pg mL−1 of cytokines measured in cultures supernatants by ELISA (a, b), or as % of control re-
sponse to MSRV-Env-T alone (c, d; in the absence of antagonist; 3534 ± 432 pg mL−1 for IL-6 and 73 ± 8 pg mL−1 for TNF-α) and are Means ± SEM from 6 to 15 experiments. e: HEK-
blue™mTLR4 cells were stimulated 24 h with increasing concentrations of MSRV-Env-T. mTLR4 activation was monitored colorimetrically using a SEAP reporter gene placed under the
control of an NF-κB inducible promoter. Data are expressed as absorbance at 650 nm and are Means ± SEM from 9 experiments. f: MSRV-Env-T (3.3 mg kg−1) is administered alone or
together with GNbAC1 (1.6mg kg−1) tomice intravenously 2 h prior blood collection, serumpreparation, and cytokines dosage. Data are expressed as pgmL−1 of cytokine released above
its basal level determined in control mice (3022 ± 590 pg mL−1 for IL-6 and 185 ± 23 pg mL−1 for TNF-α) and are Means ± EM from 9 to 10 mice per group. *P b 0.05, **P b 0.01,
***P b 0.001 versus MSRV-Env-T alone.
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HEK293 cells or hPBMC cultures in subsequent studies.
TLR are known to detect “pathogen-associated molecular patterns”
(PAMP) as LPS or viral double-stranded RNA. Recently, TLR were impli-
cated in recognizing autologous components termed “danger-associat-
ed molecular patterns” (DAMP). DAMP encompass various molecules
as HSP60 or S100A9, normally sequestered from the immune response
but released or exposed by stressed or dying cells to deliver a danger
signal (Hanke and Kielian, 2011; Vacchelli et al., 2013). MSRV-Env is
encoded by HERV genes belonging to the human genome and cannot
be classiﬁed as a classical PAMP or DAMP, but may be considered asthe ﬁrst highly potent and well characterised PAMP with an endoge-
nous origin. Although hTLR4 is generally considered as a sensor to
Gram negative bacteria, it has been shown that TLR4 is sensitive to
viral envelope proteins as respiratory syncytial virus (Rallabhandi
et al., 2012) or mouse mammary tumour virus (Burzyn et al., 2004).
The ﬁndings of this study are in line with these previous observations.
TLR4 initiates strong innate immune responses upon exposure to
LPS,mirrored by subsequent production of pro-inﬂammatory cytokines.
We performed the ﬁrst pharmacological characterisation of MSRV-Env-
T effects on cultured hPBMC and we show that it induces a
concentration-dependent release of IL-6 and TNF-α, with afﬁnities in
Fig. 5.MSRV-Env-T induced impairment of hOPC differentiation tomaturemyelinating oligodendrocytes is TLR4-dependent and inhibited by GNbAC1. a: TLR4 immunoreactivity (green)
in hOPC primary cultured for 72 h. Cell nuclei are labelled with DAPI (blue, scale bar =10 μm, a left). No staining is observed when the secondary antibody coupled to FITC is used alone
(Sec Ab, a right). b: MSRV-Env-T (3 nM), applied for 24 h or 72 h, signiﬁcantly decreases the number of CNPase and MBP positive hOPC respectively. Data are expressed as % of myelin
marker positive cells and are Means ± SEM from 3 experiments assessed in decaplicates (724 to 1118 counted cells per group). c: MSRV-Env-T induced inhibition of CNPase (black)
and MBP (grey) hOPC myelination markers expressions is inhibited by selective TLR4 antagonists. hOPC were stimulated 24 h (CNPase) or 72 h (MBP) with MSRV-Env-T (3 nM) alone
or together with GNbAC1 (50 nM), corresponding GNbAC1 vehicle or isotype (50 nM) controls, LPS-RS (300 ng mL−1), or Cli-095 (1 μM). d: Concentration-dependent inhibition of
MSRV-Env-T induced hOPC myelination impairment by GNbAC1. hOPC were stimulated 24 h (CNPase) or 72 h (MBP) with MSRV-Env-T (3 nM) alone or together with increasing con-
centrations of GNbAC1. c, d: Data are expressed as % of control response to MSRV-Env-T alone (in the absence of antagonist; inhibition of markers expressions of 15 ± 1% (c, CNPase),
30 ± 2% (c, MBP), 22 ± 2% (d, CNPase) and 29 ± 3% (d, MBP) and are Means ± SEM from 3 to 6 experiments assessed in decaplicates (c: 1112 to 2129 counted cells per group; d:
518 to 1579 counted cells per point). ***P b 0.001 versus control (b) or MSRV-Env-T alone (c).
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inhibited by all selective hTLR4 antagonists tested and behaves as a
highly potent agonist of native hTLR4. In line with these ﬁndings, we
show for the ﬁrst time that MSRV-Env-T is the molecular determinant
of MSRV pro-inﬂammatory properties in vivo as its inoculation induces
a robust release of IL-6 and TNF-α in mice.
Several studies suggest that MS has an autoimmune component and
is associated with inﬂammation as TNF-α and IL-6 are up-regulated in
MS patients' serum and/or CSF (Frei et al., 1991; Huang et al., 1999;
Maimone et al., 1991; Polachini et al., 2014; Sharief and Hentges,
1991). Independent reports showed that MSRV-Env expression is
increased in the blood of MS patients and we demonstrate here that
MSRV-Env induces a strong TLR4-dependent activation of innate
immunity. These massive pro-inﬂammatory properties appear to be
the most upstream effects of MSRV-Env which also exerts downstream
superantigen-like effects (Perron et al., 2001). The ability of
superantigens to cause antigen-independent polyclonal activation of T
lymphocytes can result in abnormal autoreactive T-cell activation
(Zhang et al., 1995) andmassive oversecretion of pro-inﬂammatory cy-
tokines (Arad et al., 2000). Superantigen properties of bacterial or viral
antigens are frequently proposed as a causative factor of autoimmune
diseases (Delogu et al., 2011; Sfriso et al., 2010; Wucherpfennig,
2001). Thus, peripheral overexpression of MSRV-Env associated withMS is clinically relevant as it may play a pivotal role by triggering
inﬂammation and the initiation of the autoimmune component of the
disease through its hTLR4 agonistic properties.
OPC are the non myelinating precursors of mature myelinating
oligodendrocytes, which are crucial for nerve conduction in the CNS
(Bradl and Lassmann, 2010). Recently, it was shown that MSRV-Env
decreases the expression of CNPase and MBP in rat OPC (Kremer et al.,
2014, 2013). Here, we show that low concentrations of MSRV-Env also
impair the expression of these myelination markers in human OPC
through hTLR4 stimulation, which strongly suggests that it impairs
hOPC differentiation to myelinating cells. Oligodendrocytes are termi-
nally differentiated, with a limited capacity to respond to injury, and
their destruction in brain lesions and disseminated demyelination are
the primary morphological features of MS (Aharoni et al., 2008;
Baumann and Pham-Dinh, 2001; Bruck et al., 2003; Compston and
Coles, 2008). Remyelination is mediated by OPC recruitment and differ-
entiation. Its failure culminates in MS, in particular in its progressive
forms (Aharoni et al., 2008; Baumann and Pham-Dinh, 2001; Bruck
et al., 2003; Keough and Yong, 2013; Polito and Reynolds, 2005; Reyn-
olds et al., 2002). Immunohistochemical analyses of post mortem
brain tissues from MS patients have evidenced MSRV-Env presence in
MS lesions, at the vicinity of hTLR4-expressing hOPC, but not in normal
appearingwhitematter or in control brains (Kremer et al., 2013; Perron
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MSRV-Env expression in MS lesions has a strong clinical relevance as
it impairs brain remyelination capacity andmay play a second causative
role in the aetiology of the disease.
MSRV-Env concentration-dependently promotes experimental
allergic encephalomyelitis (EAE), the reference animal model of MS, in
mice (Perron et al., 2013). The present study shows that MSRV-Env is
a potent pro-inﬂammatory protein with deleterious properties on
brain remyelination capacity, therefore conﬁrming its potential involve-
ment in MS physiopathology. GNbAC1, a ﬁrst-in-class recombinant
humanized monoclonal antibody targeting MSRV-Env, inhibits MSRV-
Env induced EAE (Curtin et al., 2014). Here, GNbAC1 concentration-
dependently and speciﬁcally antagonizes the activation of recombinant
hTLR4 byMSRV-Env, either produced in E. coli or in human cell line in its
glycosylated form. In addition,we show that GNbAC1 speciﬁcally blocks
the release of IL-6 and TNF-α induced byMSRV-Env in hPBMC in culture
as well as in a correspondingmurine model. This strongly suggests that
GNbAC1 can inhibit the pathogenic upstream activation of the innate
immune system by MSRV-Env, therefore blocking the autoimmune
component as well as inﬂammation in MS. Furthermore, GNbAC1 fully
antagonizes the decrease of CNPase and MBP expressions induced by
MSRV-Env in hOPC. GNbAC1 effect is speciﬁc, concentration-
dependent and highly potent, with IC50 in the nanomolar range in this
model. Thus, we propose that GNbAC1 may promote the remyelination
process impaired by MSRV-Env expressed in MS lesions. Today,
GNbAC1 has been studied in a phase I clinical trial in 33 healthy subjects
and in a phase IIa 12months study in 10 MS patients. GNbAC1 presents
favourable linear pharmacokinetics and an excellent safety proﬁle
(Derfuss et al., 2015).
In conclusion, MSRV-Env expression found in the blood and the brain
lesions of MS patients may play a pivotal role at the crossroad of patho-
logical hallmarks of the disease: chronic inﬂammation and progressive
CNS demyelination associated to remyelination impairments. For
the ﬁrst time, we demonstrate that MSRV-Env is a highly potent
and endogenous full agonist of human TLR4, which mediates its
pathogenic properties. MSRV-Env is speciﬁcally antagonised by
GNbAC1 in cellular and in vivo models, which strongly supports the
further clinical development of GNbAC1 as a targeted causal treatment
ofMS, in particular in its progressive forms dominated by remyelination
impairments.
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